Piper Sandler Maintains Overweight on aTyr Pharma, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff maintains aTyr Pharma (NASDAQ:LIFE) with an Overweight rating and raises the price target from $13 to $20.
July 21, 2023 | 9:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains an Overweight rating on aTyr Pharma and raises the price target from $13 to $20, indicating a positive outlook for the company.
The raised price target by Piper Sandler from $13 to $20 indicates a positive outlook for aTyr Pharma. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100